Agree - short term resistance from some that have been locked in at a loss. Remember this stock was $0.12 - $0.14 well before the FDA approval with no prospect of early product sales.
Lack of interest in HC only relevant to day traders.
I took up issue of new options last November.
Medium term small mkt cap, FDA (USA) and Aust Trade assisting in the marketing are all big positives.
Will post later on recent divestment.
VSG
visiomed group limited
